$Q32 Bio (QTTB.US)$Reuters· just Q32 Bio Doses First Patients in Both Part a Open-Label Extension and Part B of Signal-Aa Phase 2a Trial Evaluating Bempikibart in Alopecia Areata
$Q32 Bio (QTTB.US)$ Q32 Bio Presents Results from SIGNAL-AA Part A Clinical Trial Evaluating Bempikibart in Patients with Alopecia Areata at the 2025 American Academy of Dermatology Meeting Positive Statistically significant 16% SALT score reduction vs 2% placebo at week 24 (p=0.045) Durable response with continued improvement after treatment cessation through week 55 Clean safety profile with no Grade 3+ treatment-related adverse events Strong patient interest with multiple requests to re-initia...
$Q32 Bio (QTTB.US)$ Q32 Bio Presents Results from SIGNAL-AA Part A Clinical Trial Evaluating Bempikibart in Patients with Alopecia Areata at the 2025 American Academy of Dermatology Meeting Saturday, 8th March at 11:00 am -- Results presented in AAD late-breaker demonstrate bempikibart's encouraging improvement on SALT reduction at week 24 and continued effects after dosing cessation in patients with severe and very severe alopecia areata (AA) -- -- Durable, ongoing responses in multiple ...
$Q32 Bio (QTTB.US)$ Q32 Bio Announces Late-Breaking Presentation of Results from SIGNAL-AA Part A Clinical Trial of Bempikibart in Alopecia Areata at the 2025 American Academy of Dermatology Annual Meeting Friday, 28th February at 9:00 am -- Oral presentation to highlight Phase 2a Part A results of the randomized, placebo-controlled SIGNAL-AA clinical trial evaluating bempikibart in patients with severe and very severe alopecia areata (AA) -- WALTHAM, Mass., Feb. 28, 2025 /PRNewswire/ -- Q32 ...
Smokey The Bear
OPTree_in_Sydney
:
good potiental. did a big drop off bad news. but just hit the reversal trend! still a Bio stock analysts say worth 10-15. time to bounce back. but the swings big. very very low float and shares available.
Warren Buff
OPSmokey The Bear
:
after reading the bad news, its not THAT bad that it could cause an 80% drop on the price. I personally think that the market overreacted a bit too much
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.
U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data. U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data.
U.S. Crypto Concept Stocks U.S. Crypto Concept Stocks
Companies involved in the creation, trade, and services of digital forms of money.Displayed third-party logos, brands, or trademark images on screens or web pages are only for identification purposes and remain the property of their respective owners.Displayed third-party logos, brands, or trademark images on screens or web pages are only for identification purposes and remain the property of their respective owners. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S. Crypto Concept Stocks, ranked from highest to lowest based on real-time market data. Companies involved in the creation, trade, and services of digital forms of money.Displayed third-party logos, brands, or trademark images on screens or web pages are only for identification purposes and remain the property of their respective owners.Displayed third-party logos, brands, or trademark images on screens or web pages are only for identification purposes and remain the property of their respective owners. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S. Crypto Concept Stocks, ranked from highest to lowest based on real-time market data.
Q32 Bio Stock Forum
Breakthrough: Q32 Bio's Alopecia Treatment Maintains Effects 7 Months After Last Dose
Q32 Bio Doses First Patients in Both Part a Open-Label Extension and Part B of Signal-Aa Phase 2a Trial Evaluating Bempikibart in Alopecia Areata
Can This New Alopecia Drug Maintain Hair Growth After Treatment Stops? Q32 Bio's Trial Reveals Surprising Results
Q32 Bio Presents Results from SIGNAL-AA Part A Clinical Trial Evaluating Bempikibart in Patients with Alopecia Areata at the 2025 American Academy of Dermatology Meeting
Positive
Statistically significant 16% SALT score reduction vs 2% placebo at week 24 (p=0.045)
Durable response with continued improvement after treatment cessation through week 55
Clean safety profile with no Grade 3+ treatment-related adverse events
Strong patient interest with multiple requests to re-initia...
Q32 Bio Presents Results from SIGNAL-AA Part A Clinical Trial Evaluating Bempikibart in Patients with Alopecia Areata at the 2025 American Academy of Dermatology Meeting
Saturday, 8th March at 11:00 am
-- Results presented in AAD late-breaker demonstrate bempikibart's encouraging improvement on SALT reduction at week 24 and continued effects after dosing cessation in patients with severe and very severe alopecia areata (AA) --
-- Durable, ongoing responses in multiple ...
Q32 Bio Announces Late-Breaking Presentation of Results from SIGNAL-AA Part A Clinical Trial of Bempikibart in Alopecia Areata at the 2025 American Academy of Dermatology Annual Meeting
Friday, 28th February at 9:00 am
-- Oral presentation to highlight Phase 2a Part A results of the randomized, placebo-controlled SIGNAL-AA clinical trial evaluating bempikibart in patients with severe and very severe alopecia areata (AA) --
WALTHAM, Mass., Feb. 28, 2025 /PRNewswire/ -- Q32 ...
$Q32 Bio (QTTB.US)$
has options
nfa
$Q32 Bio (QTTB.US)$
$Richtech Robotics (RR.US)$
$SEALSQ Corp (LAES.US)$
$XTI Aerospace (XTIA.US)$
$MicroCloud Hologram (HOLO.US)$
No comment yet